CIPLA Q2 FY27 : ACTUAL VS ESTIMATES

• Net Profit: ₹852 Cr vs ₹949 Cr est. — MISS BY 10.22% 🔴

• Revenue: ₹7,404 Cr vs ₹7,498 Cr est. — MISS BY 1.25% 🔴

• EBITDA: ₹1,388 Cr vs ₹1,371 Cr est. — BEAT BY 1.24% 🟢

• EBITDA Margin: 18.7% vs 18.3% est. — BEAT BY 40 BPS 🟢

BHARAT SEATS Q2 FY27 (STANDALONE)

Net Profit: ₹15 Cr ↑54% YoY | ↑15% QoQ

Revenue: ₹709 Cr ↑55% YoY | ↑23% QoQ

Other Income: ₹1 Cr vs ₹3 Cr YoY | ₹1 Cr QoQ

Operating Profit: ₹32 Cr ↑41% YoY | ↑13% QoQ

Operating Profit Margin: 4.5% vs 4.9% YoY | 4.9% QoQ

EPS: ₹2.42 ↑53% YoY | ↑15% QoQ

BHARAT BIJLEE Q2 FY27 (STANDALONE)

• Net Profit: ₹46 Cr ↑63% YoY | ↑135% QoQ

• Revenue: ₹736 Cr ↑55% YoY | ↑35% QoQ

• Operating Profit: ₹59 Cr ↑69% YoY | ↑104% QoQ

• Margin: 8.0% vs 7.4% YoY | 5.3% QoQ

• EPS: ₹40.73 ↑63% YoY | ↑134% QoQ

IRAN AND JORDAN FOREIGN MINISTERS DISCUSS REGION IN CALL

KIRLOSKAR PNEUMATIC Q2 FY27

Net Profit: ₹40 Cr ↓9% YoY | ↑20% QoQ

Revenue: ₹326 Cr ↓16% YoY | ↑8% QoQ

Other Income: ₹8 Cr vs ₹7 Cr YoY | ₹8 Cr QoQ

EPS: ₹3.08 ↓8% YoY | ↑20% QoQ

KFIN TECH says

Stick To EBITDA Margin Guidance Of 40-45% For FY27

Morepen Laboratories Ltd – RECORD Q2 REVENUE AND EBITDA

Financial results for the quarter and half year ended September 30, 2026:

- Q2 FY27 Revenue: INR 755 Cr, up 81% YoY

- Q2 FY27 EBITDA: INR 132 Cr, up 273% YoY

- Q2 FY27 PAT: INR 89 Cr, up 117% YoY

- Q2 CDMO Revenue: INR 253 Cr (52% of API + CDMO revenue)

- Q2 Exports: INR 397 Cr, up 131% YoY

- Q2 Medical Devices: INR 208 Cr, up 65% YoY

CIPLA Q2

U.S SALES AT $ 172 MN V $ 170 MN 🟢

BBL: Q2 SL NET PROFIT 460M RUPEES VS 282M (YOY)

BBL: Q2 EBITDA 587M RUPEES VS 348M (YOY); Q2 EBITDA MARGIN 7.98% VS 7.35% (YOY)

BBL: Q2 REVENUE 7.36B RUPEES VS 4.73B (YOY)

SAUDI ARABIA CONTAINS FIRE NEAR RAS TANURA OIL HUB AFTER ATTACK

RADICO Q2 : STANDALONE NET PROFIT UP 66.2% AT ₹230.87 CR (YOY), UP 2.2% (QOQ). GOOD (ON 1ST LOOK)

Revenue up 10.4% at ₹5,582.71 Cr (YOY), down 4.9% (QOQ).
Profit before exceptional items and tax up 65.1% at ₹307.71 Cr (YOY), up 2.1% (QOQ); no exceptional items in the quarter.
Consolidated net profit up 66.5% at ₹232.35 Cr (YOY); consolidated revenue up 10.4% at ₹5,582.71 Cr (YOY).
Standalone EPS ₹17.23 v ₹10.38 (YOY); diluted ₹17.22 v ₹10.37.

RADICO KHAITAN Q2 FY27 (STANDALONE)

• Net Profit: ₹231 Cr ↑66% YoY | ↑2% QoQ

• Revenue: ₹5,583 Cr ↑10% YoY | ↓5% QoQ

• EBITDA: ₹357 Cr ↑50% YoY | ↑2% QoQ

• EBITDA Margin: 6.4% vs 4.7% YoY | 5.9% QoQ

• Other Income: ₹5 Cr

• EPS: ₹17.23 ↑66% YoY | ↑2% QoQ

CENTURY ENKA Q2 FY27

• Net Profit: ₹18 Cr ↓17% YoY | ↓70% QoQ

• Revenue: ₹558 Cr ↑37% YoY | ↑1% QoQ

• EBITDA: ₹33 Cr ↑4% YoY | ↓62% QoQ

• EBITDA Margin: 5.9% vs 7.7% YoY | 15.5% QoQ

• Other Income: ₹10 Cr

• EPS: ₹8.46 ↓17% YoY | ↓70% QoQ

RADICO KHAITAN: NET DEBT-FREE TARGET DELAYED TO H2 FY2027 FROM EARLIER Q2 FY2027 GUIDANCE, DESPITE ₹68.7 CR REDUCTION IN NET DEBT SINCE MARCH 31, 2026.

RADICO: Q2 REVENUE 17.5B RUPEES VS 15B (YOY) (EXCLUDING EXCISE DUTY)

RADICO: Q2 EBITDA 3.57B RUPEES VS 2.38B (YOY); Q2 EBITDA MARGIN 20.47% VS 15.91% (YOY) - EXCLUDING EXCISE DUTY

MANBA FINANCE Q2 FY27 (STANDALONE)

• Net Profit: ₹14 Cr ↑20% YoY | ↑4% QoQ

• NII: ₹52 Cr ↑41% YoY | ↑25% QoQ

• PPOP: ₹30 Cr ↑45% YoY | ↑24% QoQ

• Provisions: ₹8 Cr ↑53% YoY | ↑1% QoQ

• Loan Assets: ₹1,634 Cr

• EPS: ₹2.73 vs ₹2.27 YoY | ₹2.64 QoQ

RadicoKhaitan reports its Q2 earnings:

⏩Upgrade Our P&A Volume Growth Guidance To 30%

⏩Reiterate EBITDA Margin Guidance Of Around 20% For FY27

⏩Despite Challenging External Environment, Momentum Across Our Portfolio Gives Us Confidence

HUHTAMAKI INDIA Q3 CY26

• Net Profit: ₹29.73 Cr ↓19.15% YoY | ↓32.02% QoQ

• Revenue: ₹768.84 Cr ↑23.07% YoY | ↑2.51% QoQ

• EBITDA: ₹59.71 Cr ↑7.62% YoY | ↓20.53% QoQ

• EBITDA Margin: 7.77% vs 8.88% YoY | 10.02% QoQ

FII FPI LTCG TAX CUT PREOPOSAL SET ON TABLE FOR FIN MIN TO REVIEW: ZEE BUSINESS

Common guys

Don't fall for this again.
Let chart decide whats coming next!